NCT07473804 is a clinical trial in Neonatal Salt Loss, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Who is sponsoring NCT07473804?

NCT07473804 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

What condition does NCT07473804 study?

NCT07473804 studies Neonatal Salt Loss, Congenital Adrenal Hyperplasia (CAH).

Is NCT07473804 still recruiting?

NCT07473804 is currently recruiting now. Last updated 16 March 2026.

Last reviewed 2026-03-16 · How we verify

NCT07473804

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)

Recruiting now Last updated 16 March 2026

What this trial tests

trial in Neonatal Salt Loss in 25 participants. Currently enrolling.

Timeline

14 April 2025

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	25
Start date	14 April 2025
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Italy

Conditions studied

Neonatal Salt Loss — all drugs for Neonatal Salt Loss →
Congenital Adrenal Hyperplasia (CAH) — all drugs for Congenital Adrenal Hyperplasia (CAH) →

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

Adults 1 to 35, any sex, with Neonatal Salt Loss or Congenital Adrenal Hyperplasia (CAH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neonatal salt loss can be caused not only by infections but also by rare endocrine disorders that resemble 21-hydroxylase deficiency but are not detected by neonatal screening. This study examines how often these conditions occur and describes their main clinical, genetic, and treatment features.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07473804 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Last refreshed: 16 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07473804.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing